J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 M e d i c a l u s e s
2 S o c i e t y a n d c u l t u r e
T o g g l e S o c i e t y a n d c u l t u r e s u b s e c t i o n
2 . 1 L e g a l s t a t u s
2 . 2 B r a n d n a m e s
3 R e f e r e n c e s
4 E x t e r n a l l i n k s
T o g g l e t h e t a b l e o f c o n t e n t s
P e g z i l a r g i n a s e
A d d l a n g u a g e s
A d d l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Pegzilarginase , sold under the brand name Loargys , is a medication used for the treatment of hyperargininemia .[1] [2]
The most common side effects include allergic reactions.[1]
Pegzilarginase was approved for medical use in the European Union in December 2023.[2]
Medical uses
[ edit ]
Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia.[1] [2]
Society and culture
[ edit ]
Legal status
[ edit ]
In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia.[1] [1] [2]
Brand names
[ edit ]
Pegzilarginase is the international nonproprietary name .[3]
Pegzilarginase is sold under the brand name Loargys.[1]
References
[ edit ]
^ a b c d e f g "Loargys EPAR" . European Medicines Agency . 14 July 2016. Retrieved 26 December 2023 .
^ a b c d e "Loargys Product information" . Union Register of medicinal products . 18 December 2023. Retrieved 26 December 2023 .
^ World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information . 32 1 ). hdl :10665/330941
External links
[ edit ]
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Pegzilarginase&oldid=1192565338 " C a t e g o r i e s : ● O r p h a n d r u g s ● E n z y m e s u s e d a s d r u g s ● P h a r m a c o l o g y s t u b s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● U s e A m e r i c a n E n g l i s h f r o m D e c e m b e r 2 0 2 3 ● A l l W i k i p e d i a a r t i c l e s w r i t t e n i n A m e r i c a n E n g l i s h ● U s e d m y d a t e s f r o m D e c e m b e r 2 0 2 3 ● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s ● I n f o b o x d r u g a r t i c l e s w i t h o u t a s t r u c t u r e i m a g e ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t C h e m S p i d e r I D ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 3 0 D e c e m b e r 2 0 2 3 , a t 0 2 : 0 2 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
